Hyaluronidase: The Injector's Safety Net for Dissolving Filler Safely
No product has done more to make hyaluronic acid filler the dominant injectable than the enzyme that can reverse it. Hyaluronidase is the injector's safety net — the tool that turns an unpredictable outcome or an emergency into a manageable one. Understanding it fully is a core competency, not an afterthought.
How it works
Hyaluronidase is an enzyme that breaks down hyaluronic acid, accelerating the degradation of HA filler in the tissue. Its effect is relatively rapid, and it underpins two distinct clinical roles: elective correction of unwanted or poorly placed product, and the emergency dissolution central to managing vascular occlusion. One enzyme, two very different levels of urgency.
Elective correction versus emergency use
The two contexts call for different mindsets:
• Elective correction: measured dosing to refine or remove product, often staged, with the patient counselled on the possibility of over-correction
• Emergency use: high-dose, immediate flooding of an ischaemic area to restore perfusion, repeated until resolution
A crucial limitation defines its scope: hyaluronidase acts only on hyaluronic acid. It cannot reverse biostimulators such as calcium hydroxylapatite or poly-L-lactic acid, which is itself a reason to weigh product choice carefully.
The pitfalls to plan for
Hyaluronidase is not without its own considerations. Hypersensitivity and allergic reaction are recognised risks, and approaches to pre-treatment testing vary between practitioners and guidelines. Dosing is influenced by the type and volume of filler present, and results can require repeat treatment. Knowing the product's profile in advance is part of using it safely.
An essential on every shelf
Whatever the practice, hyaluronidase should be immediately available wherever HA filler is injected. Its presence is a marker of a clinic that takes complications seriously — and its confident, correct use is a hallmark of the mature injector.